November 5, 2018
First MSCopilot® results at ECTRIMS 2018
Patient acceptability of MSCopilot® was presented in a poster at ECTRIMS 2018 (Berlin).
Back to previous page
Press release
Ad Scientiam presents the first MSCopilot® results at ECTRIMS 2018
Our news
View all newsPress release
First Patient In for the HARMONY 360 study
Press releaseMyasthenia
Ad Scientiam announces a critical milestone with the enrollment of the First Patient In in the HARMONY 360 study
We announce the enrollment of the First Patient In in the HARMONY 360 study, conducted in collaboration with Merck KGaA, Darmstadt, Germany, to explore multimodal remote digital monitoring of generalized Myasthenia Gravis with MyoSense 360.
October 8, 2026
Press release
MSCopilot® interim results at EAN 2026
Press releaseMSCopilot
Ad Scientiam unveils positive 1-year interim longitudinal results for MSCopilot® at EAN 2026
At the 12th Congress of the European Academy of Neurology in Geneva, we present the first encouraging 1-year results from our MS-DETECT and MS-FLOWER studies, confirming the reliability of MSCopilot® for long-term monitoring of multiple sclerosis.
June 29, 2026
Press release
Ad Scientiam expands to the US
Press releaseMSCopilot
Ad Scientiam officially establishes presence in the United States
We announce a decisive step in our international development: the opening of our American subsidiary and the registration of MSCopilot® with the FDA.
April 16, 2026